Basic Information


GTO ID GTC3504
Trial ID NCT05938387
Disease Glioblastoma
TherapymRNA vaccine
Treatment CV09050101|CVGBM
PhasePhase1
Recruitment statusRecruiting
TitleA Phase 1 Dose-Finding Study to Evaluate Safety and Tolerability of CVGBM in Patients With Surgically Resected Glioblastoma (GBM) or Astrocytoma With a Molecular Signature of Unmethylated Glioblastoma
Year2023
CountryBelgium|Netherlands
Company sponsorCureVac
Other ID(s)CV-GBLM-001|2022-501423-25
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: CV09050101_dose level 1
Administration route intramuscular injection
Dosage CVGBM, 6μg
Age Adult, Older_Adult
Cohort2: CV09050101_dose level 2
Administration route intramuscular injection
Dosage CVGBM, 12 μg
Age Adult, Older_Adult
Cohort3: CV09050101_dose level 3
Administration route intramuscular injection
Dosage CVGBM, 25 μg
Age Adult, Older_Adult
Cohort4: CV09050101_dose level 4
Administration route intramuscular injection
Dosage CVGBM, 50 μg
Age Adult, Older_Adult
Cohort5: CV09050101_dose level 5
Administration route intramuscular injection
Dosage CVGBM, 100 μg
Age Adult, Older_Adult
Cohort6: CV09050101_RDE
Administration route intramuscular injection
Dosage CVGBM, RDE
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph